首页> 外文期刊>CNS & neurological disorders drug targets >A neuroinformatics study describing molecular interaction of Cisplatin with acetylcholinesterase: a plausible cause for anticancer drug induced neurotoxicity.
【24h】

A neuroinformatics study describing molecular interaction of Cisplatin with acetylcholinesterase: a plausible cause for anticancer drug induced neurotoxicity.

机译:一项神经信息学研究,描述了顺铂与乙酰胆碱酯酶的分子相互作用:抗癌药诱导的神经毒性的可能原因。

获取原文
获取原文并翻译 | 示例
           

摘要

Several chemotherapeutic drugs are known to cause significant clinical neurotoxicity, which can result in the early cessation of treatment. To identify and develop more effective means of neuroprotection it is important to understand the toxicity of these drugs at the molecular and cellular levels. This study describes molecular interactions between human brain acetylcholinesterase (AChE) and the well-known anti-neoplastic drug, Cisplatin. Docking between Cisplatin and AChE was performed using 'GOLD 5.0' and accessible surface area of protein before and after ligand binding was calculated by NACCESS version 2.1.1. Hydrophobic interactions and hydrogen bonds both play an equally important role in the correct positioning of Cisplatin within the 'acyl pocket' as well as 'catalytic site' of AChE to permit docking. Gold fitness score of 'Cisplatin- acyl domain of AChE' interaction and 'Cisplatin-CAS domain of AChE' interaction were 38.78 and 39.91, respectively and free binding energy was found to be -5.82 Kcal/mol and -5.79 Kcal/mol, respectively. During 'Cisplatin-CAS site of AChE enzyme' interaction, it was found that out of the three amino acids constituting the catalytic triad (S203, H447 and E334), two amino acid residues namely S203 and H447 interact with Cisplatin by hydrogen bonding and hydrophobic interaction, respectively. The values for 'accessible surface area' for the amino acid residues H447 and S203 were found to be reduced by 14.398 ?(2) and 3.894 ?(2), respectively after interaction with Cisplatin. Hence, Cisplatin might act as a potent inhibitor of AChE. Scope still remains in the determination of the three-dimensional structure of AChE-Cisplatin complex by X-ray crystallography to validate the described data. Moreover, such information may aid in the design of versatile AChE-inhibitors, and is expected to aid in safe clinical use of Cisplatin.
机译:已知几种化学治疗药物会引起明显的临床神经毒性,这可能会导致早期停止治疗。为了鉴定和开发更有效的神经保护手段,重要的是要了解这些药物在分子和细胞水平上的毒性。这项研究描述了人脑乙酰胆碱酯酶(AChE)与著名的抗肿瘤药物顺铂之间的分子相互作用。使用“ GOLD 5.0”在顺铂和AChE之间对接,并通过NACCESS 2.1.1版计算配体结合前后的蛋白质可及表面积。疏水性相互作用和氢键在顺铂在AChE的“酰基囊”和“催化位点”内正确定位中的同等重要作用,以允许对接。 “ AChE的顺铂酰基结构域”相互作用和“ AChE的顺铂-CAS结构域”相互作用的金适合度分别为38.78和39.91,自由结合能分别为-5.82 Kcal / mol和-5.79 Kcal / mol。 。在“ AChE酶的顺铂-CAS位点”相互作用期间,发现在构成催化三联体的三个氨基酸(S203,H447和E334)中,两个氨基酸残基(即S203和H447)通过氢键键合和疏水性与顺铂相互作用互动。与顺铂相互作用后,发现氨基酸残基H447和S203的“可及表面积”值分别降低了14.398?(2)和3.894?(2)。因此,顺铂可能是AChE的有效抑制剂。通过X射线晶体学确定AChE-顺铂复合物的三维结构以验证所描述的数据仍然存在范围。此外,此类信息可能有助于设计多种AChE抑制剂,并有望有助于顺铂的安全临床使用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号